Evidence map›Paper›PMID 41272532›Full record

ArticleBMC cancer2025

Establishment of a new method for detection of TROP2-positive circulating tumor cells in breast cancer.

Anqi Wang, Pingping Zeng, Tianyi Ma, Haoyuan Shi, Ruifang Li, Hang Xu, Yinghua Feng, Qiongming Liu, Mengting Wang, Tingmei Chen and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anqi Wang *Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Pingping Zeng *Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Tianyi Ma *Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Haoyuan Shi *Fujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China.
Ruifang LiCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Hang XuCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Yinghua FengCAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, CAS Key Laboratory of Standardization and Measurement for Nanotechnology, CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology, Beijing, China.
Qiongming LiuNanopep Biotech Corporation, Beijing, China.
Mengting WangNanopep Biotech Corporation, Beijing, China.
Tingmei ChenKey Laboratory of Clinical Laboratory Diagnostics (Ministry of Education), College of Laboratory Medicine, Chongqing Medical University, Chongqing, China.
Zhiyuan HuFujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China. huzy@nanoctr.cn.
Rixiong WangThe First Affiliated Hospital, Fujian Medical University, Fuzhou, China. 13960758357@fjmu.edu.cn.
Ying ZhouFujian Key Laboratory of Translational Research in Cancer and Neurodegenerative Diseases, Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, China. zhouying@fjmu.edu.cn.
Xiaopeng HaoDepartment of General Surgery, First Medical Center of Chinese PLA General Hospital, Beijing, China. hxp307@163.com.

Funding

CAS-JSPS GJHZ2094National Natural Science Foundation of China 32471456, 32027801, 31870992, 21775031Research Foundation for Advanced Talents of Fujian Medical University XRCZX2017020, XRCZX2019005Science and Technology Service Network Initiative of the Chinese Academy of Sciences KFJ-STS-ZDTP-079the Natural Science Foundation of Fujian Province 2022J01203
6 · The paper itself

Abstract

Trophoblast cell surface antigen 2 (TROP2) overexpression has been demonstrated in several tumor types, including breast cancer (BC). Circulating tumor cells (CTCs) offer a non-invasive, dynamic and real-time detection method. The detection of TROP2 expression in CTCs is significant for predicting BC progression, prognosis and the efficacy of targeted therapy. A quantitative analysis method for TROP2 of CTCs was established using our established TUMORFISHER detection platform based on epithelial cell adhesion molecule (EpCAM), and a new magnetic nanoparticle with TROP2 as the trapping target was developed, named TROP2@MNPs. The developed quantitative analysis of TROP2 was an effective method for accurately identifying the expression of TROP2 in BC cells and CTCs from BC patients, which was consistent with the data obtained by immunohistochemical (IHC) analysis. The established TROP2@MNPs could specifically capture TROP2-positive BC cells, and the capture efficiency was closely related to the expression of TROP2 in CTCs. Notably, the TROP2-based enrichment strategy was found to capture TROP2-expressing CTCs that were missed by the EpCAM-based enrichment strategy. The TROP2-targeting CTC capture platform, TROP2@MNPs, could serve as a liquid biopsy of TROP2 expression in BC patients, providing an important reference for further research on CTC-related diagnosis and individualised treatment employing TROP2-targeting drugs.

Indexed as

Antigens, NeoplasmBiomarkers, TumorBreast NeoplasmsCell Adhesion MoleculesNeoplastic Cells, CirculatingCell Line, TumorEpithelial Cell Adhesion MoleculeFemaleHumansMagnetite NanoparticlesAntigens, NeoplasmBiomarkers, TumorCell Adhesion MoleculesEPCAM protein, humanEpithelial Cell Adhesion MoleculeMagnetite NanoparticlesTACSTD2 protein, humanBreast cancerCirculating tumor cellLiquid biopsyMagnetic nanoparticleTROP2

Identifiers

PMID41272532
PMCPMC12636157

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.